MDXH
- MDxHealth SA
()
Overview
Company Summary
MDxHealth SA is a biotechnology company that specializes in developing and commercializing molecular diagnostics solutions for the early detection and management of urological cancers. The company primarily focuses on prostate cancer, which is one of the most prevalent cancers in men worldwide.
MDxHealth offers a range of diagnostic tests that aid in the stratification of patients and facilitate more personalized treatment decisions. These tests are designed to provide non-invasive and accurate results, enabling doctors to identify individuals at higher risk of disease progression or recurrence.
The company's flagship product, the ConfirmMDx for Prostate Cancer test, is used to assist urologists in identifying patients who may have hidden prostate cancer missed by previous biopsies. This test helps to reduce unnecessary repeat biopsies, improves patient care, and reduces healthcare costs.
MDxHealth also offers SelectMDx for Prostate Cancer, a urine-based molecular diagnostic test that aids in determining the need for an initial prostate biopsy in men suspected of having prostate cancer. This test helps to reduce the number of unnecessary biopsies and identifies patients at a higher risk of aggressive disease who require immediate attention.
Furthermore, MDxHealth is engaged in research and development activities to expand its product portfolio to include diagnostic tests for other urological cancers, such as bladder and renal (kidney) cancers. The company is committed to advancing precision medicine and enhancing patient outcomes through innovative molecular diagnostics.
In summary, MDxHealth SA develops and provides advanced molecular diagnostic tests that aid in the early detection, risk stratification, and management of urological cancers, primarily focusing on prostate cancer. Their solutions help improve patient care by reducing unnecessary procedures, enabling personalized treatment decisions, and enhancing overall outcomes in the field of urology.